AxoGen (AXGN) Competitors

AxoGen (NASDAQ:AXGN) and NovoCure (NASDAQ:NVCR) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their dividends, risk, analyst recommendations, earnings, profitability, media sentiment, institutional ownership and valuation.

Does the media favor AXGN or NVCR?

In the previous week, AxoGen had 1 more articles in the media than NovoCure. MarketBeat recorded 3 mentions for AxoGen and 2 mentions for NovoCure. AxoGen's average media sentiment score of 1.19 beat NovoCure's score of 0.57 indicating that AxoGen is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
AxoGen	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
NovoCure	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Which has stronger earnings & valuation, AXGN or NVCR?

AxoGen has higher earnings, but lower revenue than NovoCure. AxoGen is trading at a lower price-to-earnings ratio than NovoCure, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
AxoGen	$187.34M	2.84	-$9.96M	-$0.15	-77.80
NovoCure	$605.22M	3.09	-$168.63M	-$1.51	-11.12

Do analysts rate AXGN or NVCR?

AxoGen presently has a consensus price target of $24.50, indicating a potential upside of 109.94%. NovoCure has a consensus price target of $32.43, indicating a potential upside of 93.14%. Given AxoGen's stronger consensus rating and higher probable upside, research analysts plainly believe AxoGen is more favorable than NovoCure.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
AxoGen	0 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	3.00
NovoCure	0 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.71

Which has more risk and volatility, AXGN or NVCR?

AxoGen has a beta of 1.04, suggesting that its stock price is 4% more volatile than the S&P 500. Comparatively, NovoCure has a beta of 0.72, suggesting that its stock price is 28% less volatile than the S&P 500.

Do insiders & institutionals believe in AXGN or NVCR?

80.3% of AxoGen shares are owned by institutional investors. Comparatively, 84.6% of NovoCure shares are owned by institutional investors. 2.8% of AxoGen shares are owned by company insiders. Comparatively, 5.5% of NovoCure shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Is AXGN or NVCR more profitable?

AxoGen has a net margin of -3.68% compared to NovoCure's net margin of -26.41%. AxoGen's return on equity of -7.09% beat NovoCure's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
AxoGen	-3.68%	-7.09%	-3.67%
NovoCure	-26.41%	-45.46%	-13.34%

Summary

AxoGen beats NovoCure on 10 of the 16 factors compared between the two stocks.